European Journal of Clinical Microbiology and Infectious Diseases

, Volume 19, Issue 3, pp 187–194

Evaluation of the Inactivation of Infectious Herpes Simplex Virus by Host-Defense Peptides

  • B. Yasin
  • M. Pang
  • J. S. Turner
  • Y. Cho
  • N-N. Dinh
  • A. J. Waring
  • R. I. Lehrer
  • E. A. Wagar
Article

DOI: 10.1007/s100960050457

Cite this article as:
Yasin, B., Pang, M., Turner, J. et al. EJCMID (2000) 19: 187. doi:10.1007/s100960050457

Abstract

 A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide microplate assay was adapted to screen for the ability of 20 host-defense peptides to inactivate herpes simplex virus type 1 and type 2. The procedure required minimal amounts of material, was reproducible, and was confirmed with standard antiviral testing techniques. In screening tests, with the exception of melittin, a highly cytotoxic and hemolytic peptide found in bee venom, the α-helical peptides in our test panel (magainins, cecropins, clavanins, and LL-37) caused little viral inactivation. Several β-sheet peptides (defensins, tachyplesin, and protegrins) inactivated one or both viruses, sometimes with remarkable selectivity. Two peptides were identified as having antiviral activity against both viruses, indolicidin (a tryptophan-rich peptide from bovine neutrophils) and brevinin-1 (a peptide found in frog skin). The antiviral activity of these two peptides was confirmed with standard antiviral assays. Interestingly, the antiviral activity of brevinin-1 was maintained after reduction and carboxamidomethylation, procedures that abolished its otherwise prominent hemolytic and cytotoxic effects.

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • B. Yasin
    • 1
  • M. Pang
    • 1
  • J. S. Turner
    • 2
  • Y. Cho
    • 2
  • N-N. Dinh
    • 2
  • A. J. Waring
    • 2
  • R. I. Lehrer
    • 2
  • E. A. Wagar
    • 1
  1. 1.Department of Pathology and Laboratory Medicine, UCLA School of Medicine, CHS 1P-244, Los Angeles, CA 90095–1731, USA e-mail: ewagar@mednet.ucla.eduUS
  2. 2.Department of Medicine, UCLA School of Medicine, CHS 37–062, Los Angeles, CA 90095–1690, USAUS